Abivax's Obefazimod Achieves All Endpoints in Phase 3 Ulcerative Colitis Trial; NDA Submission Planned for Q4 2026

summarizeSummary

Abivax announced positive topline results from its Phase 3 ABTECT maintenance trial for obefazimod in ulcerative colitis, meeting all primary and key secondary endpoints and paving the way for an FDA NDA submission in late 2026.

check_boxKey Events

• Phase 3 Primary Endpoint Met

  Obefazimod met the FDA primary endpoint of placebo-adjusted clinical remission at Week 44 in both 25 mg (∆39.3%, p<0.0001) and 50 mg (∆40.3%, p<0.0001) dose regimens for moderate to severely active ulcerative colitis.

• All Key Secondary Endpoints Achieved

  Both obefazimod doses met all key secondary endpoints, including endoscopic improvement, endoscopic remission, HEMI, corticosteroid-free clinical remission, and sustained clinical remission, demonstrating robust efficacy.

• Favorable Safety Profile

  The trial showed an overall favorable safety profile with no new safety signals observed, and the treatment was generally well tolerated over the 44-week maintenance period.

• NDA Submission Planned

  Abivax intends to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for obefazimod in ulcerative colitis in late fourth quarter of 2026.

auto_awesomeAnalysis

This filing confirms highly positive Phase 3 maintenance trial results for obefazimod in ulcerative colitis, meeting both primary and all key secondary endpoints with a favorable safety profile. This successful outcome significantly de-risks the drug's path to market and positions Abivax to submit a New Drug Application (NDA) to the FDA in late Q4 2026, moving closer to potential commercialization for a major inflammatory disease.